A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma

T J Hamblin, V Inzani, S Sadullah, F K Stevenson, P Williamson, J van der Plas, P Palmer, C R Franks

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)

Abstract

Seven patients with metastatic colorectal cancer have been treated with a regimen involving an 120-hour continuous infusion of rIL-2, 3 x 10(6) mu/m2. Entry restrictions included a Karnofsky index of greater than or equal to 80%, and a measurable lesion. One patient died of peritonitis secondary to bowel perforation at the site of the unresected tumour. One patient abandoned treatment following a pulmonary embolism during the first rIL-2 infusion. Other side effects included, pyrexia, rigors, nausea, hypotension, oliguria, weight gain, thrombocytopenia, neuropsychiatric symptoms and prerenal renal failure. Two patients have shown a greater than 50% regression in the size of their tumours and 3 have stable disease. The use of 'humanized' monoclonal antibodies together with mononuclear cells from patients receiving IL-2 infusions may provide a useful way of killing tumour cells which are resistant to lysis by LAK cells.

Original languageEnglish
Pages (from-to)163-7
Number of pages5
JournalCancer Treatment Reviews
Volume16 Suppl A
Publication statusPublished - Jun 1989

Keywords

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Colorectal Neoplasms/drug therapy
  • Drug Evaluation
  • Female
  • Fluorouracil/administration & dosage
  • Humans
  • Interleukin-2/administration & dosage
  • Liver Neoplasms/diagnosis
  • Male
  • Middle Aged
  • Recombinant Proteins/administration & dosage
  • Ultrasonography

Fingerprint

Dive into the research topics of 'A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma'. Together they form a unique fingerprint.

Cite this